Mobia Medical Q2 revenue $13.5M (+102% YoY), net loss $21.0M; FY26 guide $54-56M

Mobia Medical, Inc.

Revenue $13.5M vs $6.7M in Q2 2025, up 102%; gross margin 83.2% vs 82.3%.
Net loss $21.0M ($1.10/share) vs $10.5M loss ($12.44/share) in prior year; per-share drop reflects IPO share conversion.
Cash and equivalents $177.1M as of June 30, 2026; IPO closed May 2026 with ~$134.0M net proceeds.
FY2026 revenue guidance $54-56M, implying 69-75% growth over 2025.
Published two-year VNS-REHAB follow-up data in Neurology; appointed Myriam Curet, M.D. and Reza Zadno, Ph.D. to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.